BTIG Reiterates Buy Rating on Jade Biosciences, Inc. (JBIO)

Market Context

Jade Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $14.74 with a market capitalization of $484.2M. The stock has gained 12.3% over the past 52 weeks.

Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Jade Biosciences, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Jade Biosciences, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 27, 2026	BTIG	Buy	N/A
Oct 01, 2026	Wedbush	Outperform	N/A
Oct 01, 2026	HC Wainwright & Co.	Buy	N/A
Aug 11, 2026	Wedbush	Outperform	N/A
Aug 10, 2026	BTIG	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View JBIO Stock Page